MYCL
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| MYCL proto-oncogene, bHLH transcription factor | MIM:164850 | Ensembl:ENSG00000116990 | HGNC:HGNC:7555 | PA31355 | 1p34.2 |
Gene Categories:
CLINICALLY ACTIONABLEGO terms in MYCL
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | NAS | GO:0003677 | DNA binding |
| MF | TAS | GO:0003677 | DNA binding |
| MF | IEA | GO:0046983 | protein dimerization activity |
| CC | IDA | GO:0005634 | nucleus |
| BP | IEA | GO:0006357 | regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0045607 | regulation of inner ear auditory receptor cell differentiation |
Gene expression in normal tissue: MYCL
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MYCL
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD889 | Compound 7d-cis | 10 |
| iGMDRD409 | Saracatinib | 1 |
| iGMDRD546 | BMS-754807 | 3 |
| iGMDRD427 | ABT737 | 8 |
| iGMDRD748 | PHA-665752 | 1 |
| iGMDRD152 | 179324-69-7 | 3 |
| iGMDRD687 | I-BET151 | 1 |
| iGMDRD474 | Avrainvillamide | 2 |
| iGMDRD801 | 2,4-dideoxy-DC-45-A2 | 4 |
| iGMDRD284 | Palbociclib | 1 |
| iGMDRD188 | Piperlongumine | 9 |
| iGMDRD133 | Lapatinib | 1 |
| iGMDRD399 | Selumetinib | 1 |
| iGMDRD190 | Nilotinib | 1 |
| iGMDRD584 | VER 155008 | 3 |
| iGMDRD324 | CI-1040 | 1 |
| iGMDRD330 | BRD4132 | 6 |
| iGMDRD523 | Cyanoquinoline, 11 | 5 |
| iGMDRD150 | RITA | 3 |
| iGMDRD352 | PD-0325901 | 1 |
| iGMDRD698 | Neratinib | 3 |
| iGMDRD511 | CHEMBL399379 | 2 |
| iGMDRD154 | NSC23766 | 6 |
| iGMDRD158 | NSC141540 | 5 |
| iGMDRD213 | SMR000068650 | 8 |
| iGMDRD221 | Tamoxifen | 2 |
| iGMDRD289 | Parthenolide | 10 |
| iGMDRD662 | JQ-1 | 1 |
| iGMDRD286 | Nsc 632839 | 1 |
| iGMDRD119 | Temsirolimus | 1 |
| iGMDRD67 | PENFLURIDOL | 4 |
| iGMDRD147 | Prima-1 | 6 |
| iGMDRD599 | Salermide | 5 |
| iGMDRD1008 | SR-II-138A | 10 |
| iGMDRD772 | BRD4770 | 5 |
| iGMDRD136 | Nutlin-3 | 1 |
| iGMDRD554 | CHEMBL1434137 | 3 |
| iGMDRD494 | Neopeltolide | 2 |
| iGMDRD354 | Midostaurin | 1 |
| iGMDRD144 | NSC95397 | 8 |
| iGMDRD446 | LY 2183240 | 4 |
| iGMDRD201 | SKI II | 10 |
| iGMDRD634 | SCHEMBL2608041 | 4 |
| iGMDRD280 | CYTOCHALASIN B | 14 |
| iGMDRD255 | SB225002 | 2 |
| iGMDRD134 | Sorafenib | 1 |
| iGMDRD491 | TAE-684 | 1 |
| iGMDRD138 | PX 12 | 4 |
| iGMDRD318 | PAC-1 | 6 |
| iGMDRD885 | Compound 110 | 5 |
| iGMDRD441 | TW 37 | 2 |
| iGMDRD309 | 17AAG | 1 |
| iGMDRD782 | DC-45-A2 | 3 |
| iGMDRD577 | BIX01294 | 7 |
| iGMDRD562 | Navitoclax | 8 |
| iGMDRD268 | Cerulenin | 6 |
| iGMDRD371 | THR1 Inhibitor | 1 |
| iGMDRD690 | PRIMA-1MET | 3 |
| iGMDRD60 | Quinoclamine | 3 |
| iGMDRD131 | Erlotinib | 1 |
| iGMDRD512 | nutlin 3 | 1 |
| iGMDRD148 | Pifithrin-mu | 5 |
| iGMDRD84 | Lovastatin acid | 4 |
| iGMDRD307 | Manumycin A | 8 |
| iGMDRD32 | Metformin | 1 |
| iGMDRD701 | NVP-AUY922 | 3 |
| iGMDRD456 | Crizotinib | 1 |
| iGMDRD536 | PLX-4720 | 1 |
| iGMDRD85 | Ursolic acid | 1 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 3 |
| iGMDRD68 | Paclitaxel | 1 |
| iGMDRD6 | AM-580 | 2 |
| iGMDRD82 | Quiflapon | 9 |
| iGMDRD300 | Tozasertib | 5 |
| iGMDRD179 | Shikonin | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MYCL
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.